Search clinical trials for: Anti-PD-1 monoclonal antibody

Total 7561 results

Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
Biogen

Completed

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

Healthy

Netherlands, United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer

United States
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
National Cancer Institute (NCI)

Completed

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants

Healthy

New Zealand
University of Tennessee
FDA Office of Orphan Products Development

Completed

Radioimmunoimaging of AL Amyloidosis

Primary Amyloidosis

United States
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Eye & ENT Hospital of Fudan University

Active, not recruiting

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Chemotherapy | Immunotherapy | Hypopharyngeal Carcinoma

China
Ou Bai, MD/PHD
Second Hospital of Jilin University; China-Japan Union Hospital, Jilin University

Recruiting

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Angioimmunoblastic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified

China
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)

Lung Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission

Neuroblastoma

United States
Weill Medical College of Cornell University

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Prostate Cancer

United States
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
Abramson Cancer Center at Penn Medicine
Xencor, Inc.

Active, not recruiting

XmAb20717 in Advanced Biliary Tract Cancers

Biliary Tract Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia

United States
Assiut University

Completed

Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.

Ovarian Neoplasms | Germ Cell Tumors | Immunohistochemistry

Egypt
National Cancer Institute (NCI)

Completed

Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia

United States
Jiangxi Provincial Cancer Hospital

Recruiting

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Nasopharyngeal Carcinoma

China
Memorial Sloan Kettering Cancer Center
Jazz Pharmaceuticals

Withdrawn

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Acute Lymphoblastic Leukemia (ALL) | Newly Diagnosed Philadelphia Chromosome Negative | Aged 60 Years or Older

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand, Argentina, Brazil, Canada, France, Mexico, Netherlands, Ge... and more
Shi Ming

Withdrawn

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Hepatocellular Carcinoma

China
Northwestern University
Genentech, Inc.

Completed

Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
Rockefeller University

Completed

3BNC117 and 10-1074 in HIV Uninfected Adults

Human Immunodeficiency Virus

United States
SparX Biotech(Jiangsu) Co., Ltd.

Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303)

Solid Tumor | CRC | HNSCC | RCC

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Wu Jun

Recruiting

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer

China
Zhejiang Cancer Hospital

Recruiting

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Gastric Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma | Liver Cancer Stage IV

China
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Qilu Pharmaceutical Co., Ltd.

Unknown

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

Postmenopausal Osteoporosis

China
Biocad

Completed

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Recepta Biopharma

Terminated

Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Brazil
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
Sun Yat-sen University

Not yet recruiting

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Primary Mediastinal Large B Cell Lymphoma
Y-mAbs Therapeutics
Memorial Sloan Kettering Cancer Center

Completed

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Brain Cancer | Brain Stem Glioma

United States
Xiaoming Gong

Completed

Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
National Cancer Institute (NCI)

Completed

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
University Hospital, Lille
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Effect of Anti-CD303 Antibodies in Autoimmune Diseases (ANTI-CD303)

Immune Disease

France
Yale University

Completed

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Breast Neoplasms

United States
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL95 in Advanced Malignancies.

Advanced Malignancies

China
National Cancer Institute (NCI)

Completed

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB... and other conditions

United States
Intensity Therapeutics, Inc.
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Completed

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01)

Sarcoma | Lymphoma | Breast Cancer | Head and Neck Cancer | Pancreatic Cancer | Lung Cancer | Bile Duct Cancer | Colon Cancer | Liver Cancer | Squamous Cell Carcinoma | Chordoma of Sacrum

United States, Canada
Theraclone Sciences, Inc.

Completed

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

Cytomegalovirus Infections

United States
Shanghai Mabgeek Biotech.Co.Ltd
The Second Hospital of Anhui Medical University

Active, not recruiting

Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects

Pharmacokinetics

China
Chinese PLA General Hospital

Completed

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Ovarian Cancer

China

Search clinical trials for: Anti-PD-1 monoclonal antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations